MUMBAI (Reuters) - Ranbaxy Laboratories, India's largest drugmaker by sales, reported a 90 percent drop in first quarter net profit compared to the same year-ago period, when it had exclusive rights to a generic version of cholesterol lowering drug Lipitor in the United States.
Ranbaxy said consolidated net profit fell to 1.26 billion rupees in the fiscal first quarter ended March, from 12.47 billion rupees last year. Sales fell 34.2 percent to 24.4 billion rupees.
Analysts, on an average, had estimated a net profit of 1.41 billion rupees on net sales of 26.48 billion rupees, according to I/B/E/S.
Shares in Ranbaxy were down 1 percent at 2:02 p.m.. The stock is down nearly 11 percent this year as compared to 2.4 percent rise in Mumbai market. (Reporting by Kaustubh Kulkarni; editing by Miral Fahmy)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app